Stifel analyst Thomas Shrader reiterated a Buy rating and $19 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Inovio Pharmaceuticals (INO) Overweight Rating, $31 PT Reiterated at Piper Jaffray Amid AstraZeneca DealAugust 10, 2015 11:19 AM Inovio Pharma (INO) Tops Q2 EPS by 4cAugust 10, 2015 6:53 AM Inovio Pharmaceuticals Reports 2015 Second Quarter Results; Conference Call Will Discuss New Cancer PartnershipAugust 10, 2015 6:10 AM AstraZeneca's (AZN) MedImmune to Acquire Inovio Pharma's (INO) NO-3112 Immunotherapy RightsAugust 10, 2015 6:08 AM Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmuneAugust 10, 2015 3:00 AM